The turnaround effort undertaken by Medical Imaging Centers ofAmerica continues to show signs of success (SCAN 3/15/95). TheSan Diego-based imaging services firm showed a profit for itssecond quarter (end-June), although revenues were down.
The turnaround effort undertaken by Medical Imaging Centers ofAmerica continues to show signs of success (SCAN 3/15/95). TheSan Diego-based imaging services firm showed a profit for itssecond quarter (end-June), although revenues were down.
Consolidated medical services revenues were $10.3 million,compared to $12.9 million in the second quarter of 1994, a dropof 20%. MICA posted net income of $551,000 for the quarter, comparedto a net loss of $230,000 in the same period last year.
Income from continuing operations for the second quarter was$335,000, compared to a loss from continuing operations in thesame period last year of $388,000. Discontinued operations includeMICA's Chicago-based ultrasound and nuclear medicine business,which the company has sold to Diagnostic Health Services.
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.